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An analogue of LHRH containing an extension of Gly-Cys at the carboxyl-terminus has been designed to 
permit reproducible coupling to a suitably modified carrier via a thioether bond. Potential energy calcula- 
tions indicated that this analogue adopted a conformation in solution virtually identical to the type II’ turn 
around Gly-&Leu-7 predicted for native LHRH. Intradermal administration of a conjugate of this ana- 
logue with purified protein derivative of tuberculin to male rats previously primed with BCG vaccine rapidly 
led to complete testicular regression. This adjuvant-free immunisation protocol may represent an alternative 
to castration for the veterinary control of reproductive function. 
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1. INTRODUCTION 
Luteinising hormone-releasing hormone 
(LHRH, Glp-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro- 
Gly-NH?) is secreted by the hypothalamus and is 
responsible for controlling the release of luteinis- 
ing hormone and follicle stimulating hormone 
from the pituitary [ 1,2]. Active immunisation us- 
ing a conjugate of the peptide with a suitable car- 
rier in Freund’s complete adjuvant (FCA) leads to 
the production of high titres of anti-LHRH an- 
tibodies capable of marked physiological effects in 
a number of species [3-51. These effects include a 
reduction in sex steroid levels, arrest of 
gametogenesis and atrophy of gonadal tissues 
(review [a]). 
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Autoimmunisation to LHRH may represent an 
alternative route to castration for the veterinary 
control of reproductive function [7] and for the 
clinical control of prostate carcinoma [8]. The 
practical realisation of such an approach has 
previously been frustrated by the need for 
deleterious adjuvants such as FCA, which are 
proscribed for clinical or veterinary use. In this 
paper an alternative, ‘adjuvant-free’, immunisa- 
tion protocol based on the conjugation of a novel 
analogue of LHRH with purified protein 
derivat’ive (PPD) of tuberculin [9] is described. 
2. MATERIALS AND METHODS 
2.1. Computational methods 
The conformational preferences in solution of 
LHRH and an analogue, LHRH-Gly-Cys-OH, 
were studied using the LUCIFER program for 
potential energy administration [lo]. The program 
was run on the CDC Cyber 205 computer at 
UMRCC. Solvent effects were modelled using the 
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representation previously used for the study of 
neurotensin [ 111. 
2.2. Synthesis of LHRH analogue 
LHRH-Gly-Cys-OH was synthesised by Cam- 
bridge Research Biochemicals and supplied at 85% 
purity. 
2.3. Preparation of conjugates 
LHRH-Gly-Cys-OH-PPD: 10 mg of bovine 
PPD (Batch no.291, Central Veterinary Laborato- 
ry, Weybridge) was dissolved in 0.5 ml of 0.05 M 
NaKPOd, 0.14 M NaCl, pH 7.0 (buffer A), and 
treated with 1 mg Nr-maleimidobutyryloxysucci- 
nimide (Calbiochem) previously dissolved in 5 ~1 
freshly distilled, dry dimethyl formamide. The 
mixture was stirred for 1 h at 23°C and applied to 
a column of Sephadex G25 (0.9 x 25 cm) equili- 
brated with buffer A. The modified PPD eluting in 
the excluded volume was transferred to a stop- 
pered vessel and to it was added dropwise, with 
stirring, 10 mg of LHRH-Gly-Cys-OH dissolved in 
1 ml of buffer A previously degassed and purged 
with nitrogen. The mixture was stirred at 23°C 
under nitrogen for 2 h and the amount of LHRH 
which bound to the PPD determined by estimating 
the free thiol content of the mixture at regular in- 
tervals using 5,5’-dithiobis(2nitrobenzoic acid) 
(Sigma) according to Deakin et al. [12]. A coupling 
efficiency of 65% was noted. The conjugate was 
extensively dialysed against several changes of 
distilled water at 4”C, lyophilised, and stored at 
-20°C before use. Tetanus toxoid (TT) (Well- 
come) and bovine serum albumin (BSA) (Sigma) 
were conjugated to LHRH-Gly-Cys-OH exactly as 
described for PPD above. 
2.4. Animals 
Male (A0 x DA) F1 rats, 4 months old, were ob- 
tained from the animal unit, University of Man- 
chester Medical School. 
2.5. Immunisation 
Groups of 5 rats were immunised with an 
amount of conjugate equivalent o 50/1g LHRH- 
Gly-Cys-OH according to the following schedule. 
Groups 1 and 2 received LHRH-Gly-Cys-OH-PPD 
intradermally in saline. Groups 3 and 4 received 
LHRH-Gly-Cys-OH-PPD as an alum precipitate 
subcutaneously. Groups 5 and 6 received LHRH- 
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Gly-Cys-OH-TT subcutaneously-in alum or FCA 
respectively. Group 7 received no immunisation. 
Groups 1 and 3 received BCG vaccine (Glaxo) 
equivalent to one half the human dose 1 month 
prior to the first immunisation with conjugate. Im- 
munisation consisted of a primary injection 
followed by two booster injections at 1 monthly 
intervals. Animals were bled by cannulation of the 
tail artery at fortnightly intervals for estimation of 
antibody titres, and then were killed 3 months after 
the primary immunisation, the testes removed, 
weighed and subjected to histological examination. 
Estimation of anti-LHRH antibody titre was 
achieved by ELISA using plastic microtitre plates 
coated with LHRH-Gly-Cys-OH-BSA. Assays 
were developed with 1: 1000 dilution of goat anti- 
rat IgG alkaline phosphatase conjugate. 
2.6. Histology 
Testes were fixed in neutral buffered formalin, 
embedded in paraffin wax and)5 pm sections cut. 
Sections were stained with haematoxylin and 
eosin. 
3. RESULTS 
3.1. Conformational studies 
From an extensive conformational analysis of 
mammalian LHRH, a range of conformers were 
calculated within 7.5 kcaI/mol of the predicted 
global minimum [13]. The lowest energy solution 
conformer identified has a type II ’ turn around 
Gly-6 and Leu-7 (fig.la). This compact structure 
resembles that proposed by Struthers et al. [14] 
from a molecular dynamics study, and is compati- 
ble with the activity of analogues N-methylated at 
Leu-7, constrained at the Gly-Leu linkage by a lac- 
tam ring, or containing D-enantiomer substitu- 
tions at position 6 [15]. 
While any of the predicted low energy con- 
formers could represent the receptor-bound, 
bioactive form, the Boltzmann distribution in- 
dicates that the lowest energy form would 
predominate in solution, and therefore it is against 
the three-dimensional surface features of this con- 
former that the bulk of antibodies will be raised. 
A design method previously employed is to 
energy minimise a range of analogues and to cor- 
relate relative biological potencies with the relative 
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Fig.1. Stereoscopic diagrams of the predicted lowest energy solution conformers of (a) mammalian LHRH, and (b) the 
LHRH-Gly-Cys-OH analogue. 
energetic preferences of the analogues for par- 
ticular conformer classes [ 161. An extension of this 
approach is that the predicted global minimum 
structure of the native peptide can be used as a 
‘template’ to test energetic preferences on inclu- 
sion of active residue substitutions [17]. In the pre- 
sent case a C-terminal extension of Gly-Cys was 
added to the template, and after energy minimisa- 
tion little deviation in overall arrangement of the 
molecule was noted (fig.lb). The ability of an- 
tibodies raised against the LHRH-Gly-Cys-OH- 
PPD to cross-react with endogenous LHRH sup- 
ports this prediction in gross terms, with the reser- 
vation that the effects of the carrier were not 
included in the simulation. 
3.2. Antibody titres to LHRH 
Each of the groups of rats immunised with 
LHRH-Gly-Cys-OH conjugates gave an antibody 
response to the hormone detectable by ELBA. 
Fig.2 shows antibody titres at week 10 for each 
group. Immunisation with the conjugate of 
LHRH-Gly-Cys-OH-TT led to significant an- 
tibody levels, and these were higher in the group 
receiving conjugate in FCA. Although all four 
groups of rats receiving LHRH-Gly-Cys-OH-PPD 
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Fig.2. Day 70 anti-LHRH-Gly-Cys-OH antibody titres in rats immunised with various LHRH-Gly-Cys-OH conjugates. 
gave antibody responses, responses in those groups 
(1 and 3) previously primed with BCG titres were 
considerably higher than in those which were not 
(2 and 4). LHRH-Gly-Cys-OH-PPD given in- 
tradermally was a very poor immunogen in normal 
rats, but in the BCG-primed animals led to the 
highest itre of antibody seen in any of the groups. 
LHRH-Gly-Cys-OH-PPD absorbed onto alum 
and given subcutaneously led to significant an- 
tibody production in normal rats, but in the BCG- 
primed rats the response was inferior to that ob- 
tained with the soluble antigen given in- 
tradermally. 
3.3. Physiological effects of immunisation to 
LHRH 
Mean testis weights for individual rats in each 
group are shown in fig.3. Marked testicular egres- 
sion was apparent in all members of the group 
receiving soluble LHRH-Gly-Cys-OH-PPD after 
BCG priming and also in the group treated with 
LHRH-Gly-Cys-OH-TT in FCA although, here, 
one animal showed no effects. Less marked effects 
68 
were seen in group 3 (2 of 5) and group 5 (1 of 5). 
Histological examination of testes revealed that in 
those individuals exhibiting severe regression there 
was evidence of marked atrophy of seminiferous 
tubules and absence of spermatogenesis. 
4. DISCUSSION 
The autoimmunisation protocol presented here 
has two advantages over previous procedures. 
Firstly it does not rely on proscribed adjuvants, 
and therefore is potentially suitable for clinical and 
veterinary applications. Secondly, the preliminary 
results would indicate that this schedule is more ef- 
fective than other approaches, since rapid and 
complete testicular regression was noted in all five 
animals receiving the new treatment. 
The efficacy of the new procedure may be partly 
attributable to the method of conjugation 
employed. Hitherto published procedures for the 
conjugation of LHRH to a carrier have generally 
involved the condensation of the native peptide 
with a water-soluble carbodiimide (WSC). The 








Fig.3. Effect of immunisation with various LHRH-Gly- 
Cys-OH conjugates on testicular weight in rats. 
absence of free carboxyl or amino moieties in 
LHRH means that coupling is probably effected 
through the hydroxyl group of Ser4, or via a car- 
boxymethylated derivative of His-2. As a result the 
immunogen is poorly defined, and there is a 
danger that the peptide is attached through a 
region important for the immunological recogni- 
tion of the endogenous hormone. 
The novel analogue employed here contains an 
extension of Gly-Cys at the C-terminus to permit 
reproducible coupling to the carrier via the cysteine 
side chain. The conformational studies have been 
valuable as a design tool by showing that the 
analogue maintains the type II ’ turn predicted for 
the native peptide, and although it is possible that 
conjugation will influence the solution structure of 
the analogue, the extension is both flexible and of 
sufficient length to hold the peptide away from the 
surface of the carrier. 
PPD of tuberculin is an excellent carrier for pep- 
tide antigens when used in recipients previously 
primed with BCG [9]. The mechanism of action is 
not known, but it is most likely that it is the induc- 
tion of a local inflammatory reaction to the carrier 
which leads to a particularly vigorous response to 
the peptide. Nevertheless, the use of the extended 
analogue would seem to be crucial for the success 
of these experiments, since a conjugate of LHRH 
and PPD prepared using the native peptide and 
WSC was unable to induce a physiological 
response in immunised animals (not shown). D- 
Lys-6-LHRH conjugated to PPD with glutaralde- 
hyde has likewise been found to be ineffective. It 
should also be noted that the intradermal route of 
immunisation appears to be important: the same 
antigen injected as an alum suspension was less ef- 
fective at immunocastration. 
The advantages of the immunisation schedule 
described above make this procedure potentially 
suitable for clinical or veterinary use. Although a 
totally synthetic LHRH vaccine based on muramyl 
dipeptide (MDP) has recently been shown to effect 
immunological castration in male mice [ 18,191, the 
apparent pyrogenic effects of MDP may prove to 
be a drawback with this approach. Further studies 
on the dose requirements for the LHRH-Gly-Cys- 
OH-PPD procedure are currently in progress, and 
will be presented elsewhere. 
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